Multidimensional phenotyping of the post-COVID-19 syndrome: A Swiss survey study.


Journal

CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265

Informations de publication

Date de publication:
12 2022
Historique:
revised: 26 07 2022
received: 10 06 2022
accepted: 27 07 2022
pubmed: 18 8 2022
medline: 4 11 2022
entrez: 17 8 2022
Statut: ppublish

Résumé

Post-COVID-19 syndrome affects approximately 10-25% of people after a COVID-19 infection, irrespective of initial COVID-19 severity. The aim of this project was to assess the clinical characteristics, course, and prognosis of post-COVID-19 syndrome using a systematic multidimensional approach. An online survey of people with suspected and confirmed COVID-19 and post-COVID-19 syndrome, distributed via Swiss COVID-19 support groups, social media, and our post-COVID-19 consultation, was performed. A total of 8 post-infectious domains were assessed with 120 questions. Data were collected from October 15 to December 12, 2021, and 309 participants were included. Analysis of clinical phenomenology of post-COVID-19 syndrome was performed using comparative statistics. The three most prevalent post-COVID-19 symptoms in our survey cohort were fatigue (288/309, 93.2%), pain including headache (218/309, 70.6%), and sleep-wake disturbances (mainly insomnia and excessive daytime sleepiness, 145/309, 46.9%). Post-COVID-19 syndrome had an impact on work ability, as more than half of the respondents (168/268, 62.7%) reported an inability to work, which lasted on average 26.6 weeks (95% CI 23.5-29.6, range 1-94, n = 168). Quality of life measured by WHO-5 Well-being Index was overall low in respondents with post-COVID-19 syndrome (mean, 95% CI 9.1 [8.5-9.8], range 1-25, n = 239). Fatigue, pain, and sleep-wake disturbances were the main symptoms of the post-COVID-19 syndrome in our cohort and had an impact on the quality of life and ability to work in a majority of patients. However, survey respondents reported a significant reduction in symptoms over 12 months. Post-COVID-19 syndrome remains a significant challenge. Further studies to characterize this syndrome and to explore therapeutic options are therefore urgently needed.

Identifiants

pubmed: 35975339
doi: 10.1111/cns.13938
pmc: PMC9538958
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1953-1963

Informations de copyright

© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

Références

WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
Data, O.W.I. Statistics and Research: Coronavirus Pandemic (COVID-19) - the Data. https://ourworldindata.org/coronavirus-data?country=~OWID_WRL.
UK Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications
WHO World Population. Global Health Observatory https://www.who.int/data/gho/data/indicators/indicator-details/GHO/population-(in-thousands)
SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf
Hoffman LA, Vilensky JA. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140(8):2246-2251.
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784.
Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.
Dennis A, Wamil M, Alberts J, COVERSCAN study investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391.
Jacobson KB, Rao M, Bonilla H, et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis. 2021;73(3):e826-e829.
Centers for Disease Control and Prevention: Post-exertional malaise (PEM). https://www.cdc.gov/me-cfs/healthcare-providers/clinical-care-patients-mecfs/treating-most-disruptive-symptoms.html.
National Institute for Health and Care Excellence. Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management-In Development. [GID-NG10091]. 2021. https://www.nice.org.uk/guidance/indevelopment/gid-ng10091
Altea Long COVID Network. https://www.altea-network.com/
Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the fatigue severity scale in a swiss cohort. Sleep. 2008;31(11):1601-1607.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
Morin CM, Belleville G, Bélanger L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-608.
Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-176.
Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216.
Hives L, Bradley A, Richards J, et al. Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. BMJ Open. 2017;7(11):e017521.
Jiang Z, Zhu PP, Wang LY, et al. Psychological distress and sleep quality of COVID-19 patients in Wuhan, a lockdown city as the epicenter of COVID-19. J Psychiatr Res. 2021;136:595-602.
Mandal S, Barnett J, Brill SE, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396-398.
Poyraz BC, Poyraz CA, Olgun Y, et al. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2021;295:113604.
Coronavirus Krankheit 2019 (COVID-19). Epidemiologische Zwischenbilanz zum neuen Coronavirus in der Schweiz und im Fürstentum Liechtenstein Stand 27.04.2020, 8:00 Uhr. https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html
Su Y. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881-895.e20.
Wuthrich B. Epidemiology of allergies in Switzerland. Ther Umsch. 2001;58(5):253-258.
Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol. 2022;94(1):253-262.
Poudel AN, Zhu S, Cooper N, et al. Impact of Covid-19 on health-related quality of life of patients: a structured review. PLoS One. 2021;16(10):e0259164.
Tsuzuki S et al. Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients. medRxiv. 2021;27(9):21264225.
Menon V, Muraleedharan A. Internet-based surveys: relevance, methodological considerations and troubleshooting strategies. Gen Psychiatr. 2020;33(5):e100264.

Auteurs

Lara Diem (L)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Anina Schwarzwald (A)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Christoph Friedli (C)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Helly Hammer (H)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Livia Gomes-Fregolente (L)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Graduate School for Health Sciences, University of Bern, Bern, Switzerland.

Jan Warncke (J)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Lea Weber (L)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Nicole Kamber (N)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Andrew Chan (A)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Claudio Bassetti (C)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Anke Salmen (A)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Robert Hoepner (R)

Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH